White House Turns Sewers Into Drug Radar

The White House’s new plan to track drug use through America’s sewers is being sold as “lifesaving” intelligence—but it also raises a familiar question: how much federal surveillance is too much?

Quick Take

ONDCP is using wastewater testing to spot drug trends within days, aiming to beat the months-long lag of clinical and overdose reporting.
A one-year federal contract worth $615,700 tapped Biobot Analytics to provide nationwide wastewater “intelligence” covering 20+ chemical targets, including fentanyl and stimulants.
Supporters argue the data stays anonymous at the community level, but research warns that narrow sampling could increase risks of targeting specific neighborhoods.
The administration says the approach supports both demand-side treatment targeting and supply-side insights tied to trafficking and production patterns.

What the White House is building—and why it matters now

The White House Office of National Drug Control Policy is expanding a strategy that treats wastewater as a near real-time indicator of community drug use. The concept borrows from COVID-era sewage monitoring, but applies it to opioids, stimulants, and emerging compounds. The stated goal is faster situational awareness, because traditional indicators like toxicology reports and hospitalization data can arrive weeks or months after a surge begins, limiting rapid local response.

ONDCP’s partnership with Biobot Analytics formalizes that approach at a national scale. The federal contract began in September 2025 and runs for one year, valued at $615,700. Biobot has said its platform can track more than 20 chemical targets, including fentanyl, cocaine, and other drug classes, as well as certain treatment-related compounds. Federal officials describe the output as “wastewater intelligence” intended to guide faster decisions across agencies and communities.

How wastewater data can change the speed of public health response

Wastewater-based epidemiology is designed for speed and breadth, not individual identification. Sampling at a wastewater treatment facility aggregates signals from thousands of residents, allowing analysts to detect shifts in consumption patterns within business days. Biobot’s epidemiology leadership has argued that this time advantage matters because local health departments often receive confirmed overdose counts far too late to surge resources, warn the public, or adjust outreach before a wave of harm peaks.

NIDA-backed research and development from 2020 through 2024 helped validate the concept, including claims that wastewater signals can show shifts in drug use earlier than many traditional indicators. For policymakers, that creates a tempting promise: move from reactive crisis management to proactive prevention. For taxpayers, the relevant question is whether the federal government will translate early warnings into measurable outcomes—reduced overdoses, more effective treatment placement, and smarter use of limited funds.

Where “public health” ends and surveillance concerns begin

Wastewater monitoring is frequently described as anonymous, but the privacy debate depends on how and where sampling occurs. Peer-reviewed analysis has warned that increasingly granular sampling—especially upstream from a large treatment plant—could narrow the focus to smaller geographic areas. Even without naming individuals, that can intensify political and social pressures on specific neighborhoods, raising concerns about equity, stigma, and the potential for misuse by institutions that are not accountable to local voters.

That risk lands in a broader moment of low public trust. Many Americans across the political spectrum already believe federal programs expand quietly, then outlive the crisis that justified them. Conservatives tend to focus on mission creep and bureaucratic overreach, while many on the left worry about selective enforcement and discrimination. Because ONDCP coordinates activity across numerous federal agencies, clear guardrails on access, retention, and downstream use of data will matter as much as the technology itself.

AI and “more treatment”: promises, gaps, and the need for accountability

Headlines about the strategy mention artificial intelligence and expanded treatment, but the most concrete public details currently emphasize wastewater testing and data integration. The plan is described as complementing existing systems that track overdoses, hospitalizations, toxicology, and survey results. Publicly available summaries provide limited specifics on the AI component and limited clarity on which treatment expansions will be funded, where, and on what timeline, making performance evaluation difficult.

ONDCP leadership has said wastewater insights can also support supply-side objectives, including understanding drug production and trafficking patterns, and the federal budget materials describe work that includes wastewater monitoring at sites along the U.S. southwest border. If policymakers use those signals to steer resources toward interdiction and treatment simultaneously, the approach could strengthen public safety. If the data becomes another opaque federal dashboard, public skepticism will deepen—fairly or not.

The core test will be governance: who sees the data, how precisely it can be localized, and what rules prevent it from becoming a political tool. Wastewater surveillance may help officials act faster against fentanyl and other deadly drugs, but speed alone is not a substitute for constitutional instincts and transparent oversight. In a country weary of top-down “expert” solutions, the public will want proof the program saves lives without quietly expanding government power.